Article Text

Download PDFPDF
Selective tumour necrosis factor receptor-1 inhibition in acute lung injury: a new hope or a false dawn?

Statistics from Altmetric.com

Footnotes

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests LBW receives consulting fees from CSL Behring. She also has research funding from Boehringer Ingelheim and Global Blood Therapeutics.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles